ACAD Q4 2021 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$131M+8.1% YoY

Gross Profit

$128M98.0% margin

Operating Income

-$45M-34.2% margin

Net Income

-$43M-33.0% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-0.6%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$700M

Total Liabilities

$159M

Stockholders' Equity

$541M

Cash & Equivalents

$147M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$131M	$121M	+8.1%
Gross Profit	$128M	$116M	+10.8%
Operating Income	-$45M	-$67M	+33.5%
Net Income	-$43M	-$67M	+35.4%